Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527693 | 1.00 | GPR119 (0.41) | GPR119KDM4ESSTR4PIK3CDIDO1 | |
| SCHEMBL25888707 | 0.85 | GPR119 (0.43) | GPR119KDM4EIDO1PIK3CA | |
| SCHEMBL25306591 | 0.81 | JAK1 (0.44) | GPR119KDM4EIDO1 | |
| SCHEMBL26124046 | 0.81 | GPR119 (0.45) | GPR119KDM4EIDO1PIK3CA | |
| SCHEMBL30599815 | 0.81 | GPR119 (0.45) | GPR119KDM4EIDO1PIK3CA | |
| SCHEMBL29305267 | 0.78 | CYP1A2 (0.38) | GPR119SSTR4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL30037992 | 0.78 | CYP1A2 (0.38) | GPR119SSTR4PIK3CDPIK3CAPIK3CB | |
| SCHEMBL25309310 | 0.78 | GPR119 (0.47) | GPR119KDM4EIDO1PDE4B | |
| SCHEMBL25888629 | 0.78 | PDE4B (0.43) | GPR119KDM4EIDO1PDE4B | |
| SCHEMBL31654522 | 0.77 | GPR119 (0.47) | GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | GPR119 399/4885KDM4E 1488/4885SSTR4 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.